Clinical Trial Update: ctDNA in HER2+ EBC Neoadjuvant Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating circulating tumor DNA (ctDNA) as a biomarker in HER2-positive early breast cancer during neoadjuvant treatment. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING